Given that insulin/IGF signaling is known to contribute to obesity-associated cancer, further investigation regarding the efficacy of drugs targeting this system and its downstream effectors in the obese patient population is warranted. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.